Immunitas Therapeutics, a single cell genomics-based therapeutics company, announced $58M in a Series B funding led by Agent Capital. Other participants include the following: Medical Excellence Capital, 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge, and The Leukemia & Lymphoma Society Therapy Acceleration Program. Existing investors in Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund, and Longwood Fund also contributed in the financing.

The Series B funding will be used to advance Immunitas' lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies. The company expects to file its first Investigational New Drug application (IND) in 1H 2022 for IMT-009. This financing builds on the $39 million Series A financing secured in 2019.